logo
I stopped taking Mounjaro for 2 weeks & here's what really happens – yes, I've gained weight and I was ‘uncontrollable'

I stopped taking Mounjaro for 2 weeks & here's what really happens – yes, I've gained weight and I was ‘uncontrollable'

Scottish Sun08-07-2025
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
AFTER ditching Mounjaro for two weeks to go on holiday, a mother has shared what really happens when you stop taking fat jabs.
Carmel Elizabeth Smith, a mother from the UK, weighed 16 stone before she started using the injections in a bid to slim down.
Sign up for Scottish Sun
newsletter
Sign up
3
A mother has revealed what really happens when you stop taking Mounjaro
Credit: TikTok/mounjarojourneyandme2
3
Carmel Elizabeth Smith got candid on being 'uncontrollable' and shared exactly how much weight she put back on after ditching the injections for just two weeks
Credit: TikTok/mounjarojourneyandme2
3
Mounjaro is used to treat type 2 diabetes
Credit: Getty
Now, the pink-haired beauty, who was previously suffering from pre-diabetes and high cholesterol, has not only reversed these conditions, but has lost four stone and has dropped down to just 12 stone.
But Carmel was eager to set the record straight on what she has recently experienced after she stopped injecting.
Posting on social media, the savvy mum explained: 'So I went on holiday and didn't take Mounjaro for two weeks - I just wanna share what happened when I came off.
'For all the people thinking 'does the appetite come back?' Absolutely, absolutely.'
Mounjaro, which is known as the King Kong of jabs, is now being prescribed on the NHS in the first anti-obesity rollout of its kind.
It is said to suppress the ­appetite, making people feel fuller for longer.
Such injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese - with a Body Mass Index of 30 or over.
One jab is administered each week but the duration is dependent on a person's weight.
But the content creator explained that she became 'uncontrollable' when it came to eating after stopping the injections, as she added: 'For the first five days on holiday, I was fine, I was just eating my normal little appetite - got to about day six and I started having some dinners, then it started to be little snacks in between.'
After two weeks, Carmel had put on 8lbs, as she explained: 'I got home and I don't know what happened, but I was uncontrollable - crisps, Haribo's, sweets, cake.'
Sun Health Explainer: Fat jabs
Now, Carmel is back on Mounjaro and luckily, is beginning to see her weight decrease again.
'Back on it and starting to lose again - but yeah, when you stop taking Mounjaro, God help," she confirmed.
Social media users react
Carmel's TikTok clip, which was posted under the username @mounjarojourneyandme2, has clearly left many open-mouthed, as at the time of writing, it had quickly racked up 223,700 views in just three days.
Not only this, but it had also amassed 1,158 likes and 315 comments.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Social media users were stunned by Carmel's claims and many eagerly flocked to the comments to share their thoughts.
One person said: 'Thank you for this. I'm going away in a few weeks for two weeks and wasn't sure whether to stop or not but now I'm going to stay on it. For me personally, I'd rather eat a bit less on holiday as it's been so hard for me to lose weight over the last nine months. I'd be devastated if I ended up putting on weight while I was away.'
Another added: 'I'm thinking I'm gonna have to be on this for life.'
When you stop taking Mounjaro, God help
Carmel Elizabeth Smith
A third commented: 'I was fine for six weeks then bang…uncontrollable hunger.'
Whilst someone else wrote: 'I'd never ever stop, it's not worth it, I did it once because of finance but I'd never do it on purpose.'
Meanwhile, another user questioned: 'So does this mean you are trapped in the expensive money go round?'
To this, Carmel replied and confirmed: 'Looks that way.'
The reality of Mounjaro
Although many have boasted about weight loss success since using Mounjaro, last year it was revealed that Scots nurse Susan McGowan, 58, died after taking low-dose injections of Mounjaro over a fortnight.
A probe also found that nearly 400 people have gone to hospital after taking weight loss drugs.
The common side effects include nausea, vomiting and diarrhoea, which can lead to severe dehydration.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
And if that wasn't bad enough, doctors say they have also seen 'life-threatening complications', including seizures, bowel obstruction and inflammation of the pancreas.
Model Lottie Moss, 27, even said she had a seizure after taking high doses of Ozempic.
The makers of Mounjaro, Lilly UK, said patient safety is its 'top priority'.
Lilly UK stressed: 'Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.
'If anyone is experiencing side effects when taking any Lilly medicine, they should talk to their doctor or other healthcare professional.'
Unlock even more award-winning articles as The Sun launches brand new membership programme - Sun Club
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming unsustainable, say pharmacists

The Guardian

timean hour ago

  • The Guardian

Demand for weight loss drugs is becoming unsustainable, say pharmacists

Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.

Pharmacies warn of unsustainable demand for weight loss medication
Pharmacies warn of unsustainable demand for weight loss medication

South Wales Guardian

time2 hours ago

  • South Wales Guardian

Pharmacies warn of unsustainable demand for weight loss medication

Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Pharmacies warn of unsustainable demand for weight loss medication
Pharmacies warn of unsustainable demand for weight loss medication

Leader Live

time3 hours ago

  • Leader Live

Pharmacies warn of unsustainable demand for weight loss medication

Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store